Item 2.02. Results of Operations and Financial Condition.



On January 8, 2023, Esperion Therapeutics, Inc. issued a press release
announcing preliminary 2022 results and upcoming corporate milestones. A copy of
the press release is attached hereto as Exhibit 99.1 and is incorporated into
this Item 2.02 by reference.

The information in this Current Report on Form 8-K and Exhibit 99.1 attached
hereto is intended to be furnished and shall not be deemed "filed" for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange
Act") or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933,
as amended, or the Exchange Act, except as expressly set forth by specific
reference in such filing.

Item 9.01. Financial Statements and Exhibits.



Exhibit No.                                               Description

      99.1                 Press Release dated January     8    , 202    3    .

       104               The cover page from this Current Report on Form

8-K, formatted in Inline XBRL.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses